Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
affected more than 529 million people, and today the world is facing different mutant strains …

The COVID-19 pandemic represents one of the biggest challenges of the 21st century. In
addition to the general effect on society and health-care systems, patients with systemic …

Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The
evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced …

Background We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …

Introduction The effect of tixagevimab/cilgavimab (Evusheld™; AstraZeneca, UK) should be
evaluated in the context of concurrent outbreak situations. Methods For serologic …

Abstract Background Regdanvimab (CT-P59) is a neutralizing antibody authorized in
Republic of Korea for the treatment of adult patients with moderate or mild-COVID-19 who …

Background Immune-evading severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) variants are emerging continuously. The clinical effectiveness of monoclonal antibody …

Coronavirus disease (COVID-19), which is caused by SARS-CoV-2, is the biggest challenge
to the global public health and economy in recent years. Until now, only limited therapeutic …

Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), an infectious disease that has become a serious burden on …

We read with great interest that biologic medications might be a promising therapeutic
option in COVID-19. 1 Neutralizing monoclonal antibodies such as regdanvimab can reduce …